Document:

<PAGE>

                                                                    EXHIBIT 10.3

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT
AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THE SECURITIES
MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN
EXEMPTION THEREFROM. THE SECURITIES REPRESENTED BY THIS CERTIFICATE AND THE
RIGHTS OF THE HOLDER HEREOF ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND
OTHER RESTRICTIONS, AND THE HOLDER OF THE SECURITIES REPRESENTED BY THIS
CERTIFICATE (INCLUDING ANY FUTURE HOLDER) IS BOUND BY THE TERMS OF A WARRANT
PURCHASE AGREEMENT BETWEEN THE ORIGINAL PURCHASER AND THE COMPANY (COPIES OF
WHICH MAY BE OBTAINED FROM THE COMPANY).

              WARRANT TO PURCHASE 200,000 SHARES OF COMMON STOCK OF
                                  VIACELL, INC.

      This certifies that the holder hereof (the "Holder"), for value received,
is entitled to purchase from ViaCell, Inc., a Delaware corporation (the
"Company"), Two Hundred Thousand (200,000) fully paid and nonassessable shares
(the "Warrant Shares") of the Company's common stock, par value $0.01 per share
(the "Common Stock"), at a price of $7.85 per share (the "Stock Purchase Price")
pursuant to that certain Warrant Purchase Agreement between the Company and
Purchaser, dated as of August 29,2005 (the "Warrant Purchase Agreement") at any
time on or after the date the Company first administers a G-CSF Product (as
defined in that certain Amendment No. 1 to the Collaboration Agreement (the
"Amendment") by and between the Company and Holder) in Phase II Clinical Trials
(the "Vesting Date"), up to and including 5:00 p.m. (California time) on the
Expiration Date (as defined below), upon (a) surrender to the Company at its
principal offices at 245 First Street, Cambridge, Massachusetts 02142 (or at
such other location as the Company may advise the Holder in writing) of this
Warrant properly endorsed with the Notice of Conversion attached hereto duly
completed and signed, and (b) payment of the aggregate Stock Purchase Price for
the Warrant Shares. The Stock Purchase Price and the number of shares
purchasable hereunder are subject to adjustment as provided in Section 3 of this
Warrant. "Expiration Date" shall mean August 29,2012 (or, in the event that
August 29, 2012 is not a business day, the next succeeding business day).

      This Warrant may be exercised as a whole or may be exercised in part or
from time to time at any time after the Vesting Date.

      This Warrant is issued pursuant to, and subject of the provisions of, the
Warrant Purchase Agreement and, by its acceptance of this Warrant, the Holder
expressly agrees to comply with the provisions of the Warrant Purchase
Agreement. Terms used but not defined in this Warrant shall have the respective
meanings assigned to them in the Warrant Purchase Agreement, to which reference
is hereby made.

                                        1

<PAGE>

      This Warrant is subject to the following further terms and conditions:

      1.    EXERCISE.

            Exercise Procedure; Issuance of Certificates; Payment for Shares.
This Warrant is exercisable at the option of the Holder at any time on or after
the Vesting Date and prior to or on the Expiration Date for the Warrant Shares
which may be purchased hereunder. The Company agrees that the Warrant Shares
purchased under this Warrant shall be and are deemed to be issued to the Holder
as the record owner of such shares as of the close of business on the date on
which this Warrant shall have been surrendered and payment made for such shares.
Subject to the provisions of Section 2 hereof, certificates for the Warrant
Shares so purchased, together with any other securities or property to which the
Holder is entitled upon such exercise, shall be delivered to the Holder by the
Company's transfer agent at the Company's expense within a reasonable time after
the rights represented by this Warrant have been exercised. Each stock
certificate so delivered shall be in such denominations of Warrant Shares as may
be requested by the Holder and shall be registered in the name of the Holder.

            If the Warrant shall be converted for less than the total number of
shares of Warrant Shares then issuable upon conversion, promptly after surrender
of the Warrant upon such conversion, the Company will execute and deliver a new
warrant, dated the date hereof, evidencing the right of the Holder to the
balance of the Warrant Shares purchasable hereunder upon the same terms and
conditions set forth herein. If this Warrant is converted, as a whole or in
part, after the occurrence of an event as to which Section 3.8 is applicable,
the Holder shall receive the consideration contemplated by Section 3.8 in lieu
of Common Stock of the Company.

      2.    SHARES TO BE FULLY PAID; RESERVATION OF SHARES.

            The Company covenants and agrees that all Warrant Shares which may
be issued upon the exercise of this Warrant will, upon issuance, be validly
issued, fully paid and nonassessable and free from all preemptive or any similar
rights of any stockholder of the Company and free of any liens or encumbrances
arising through the Company, other than restrictions of transfer under the
Warrant Purchase Agreement, this Warrant and applicable state and federal
securities laws. The Company further covenants and agrees that during the period
within which this Warrant may be exercised the Company will at all times have
authorized and reserved, for the purpose of issue or transfer upon exercise of
this Warrant, a sufficient number of authorized but unissued shares of Common
Stock, when and as required to provide for the exercise of the rights
represented by this Warrant. The Company will take all such action as may be
necessary to assure that such shares of Common Stock may be issued as provided
herein without violation of any applicable law or regulation, or of any
requirements of any domestic securities exchange or automated quotation system
upon which the Common Stock is listed.

      3.    ADJUSTMENT OF STOCK PURCHASE PRICE AND NUMBER OF WARRANT SHARES
            ISSUABLE.

            The Stock Purchase Price and the number of Warrant Shares issuable
upon the exercise of each Warrant are subject to adjustment from time to time
upon the occurrence of the events enumerated in this Section 3.

                                        2

<PAGE>

            3.1 Adjustment for Change in Capital Stock. If the Company: (i) pays
a dividend or makes a distribution on its Common Stock in shares of its Common
Stock; (ii) subdivides its outstanding shares of Common Stock into a greater
number of shares; or (iii) combines its outstanding shares of Common Stock into
a smaller number of shares; then the Stock Purchase Price in effect immediately
prior to such action shall then be adjusted in accordance with the formula:

             E(1) = E x O/A

where:

             E(1) = the adjusted Stock Purchase Price.

             E    = the current Stock Purchase Price.

             O    = the number of shares of Common Stock outstanding prior to
                    such action.

             A    = the number of shares of Common Stock outstanding immediately
                    after such action.

            (a) In the case of a dividend or distribution the adjustment shall
become effective immediately after the record date for determination of holders
of shares of Common Stock entitled to receive such dividend or distribution, and
in the case of a subdivision or combination, the adjustment shall become
effective immediately after the effective date of such corporate action.

            (b) If after an adjustment the Holder of the Warrant upon exercise
of it may receive shares of two or more classes of capital stock of the Company,
the Company shall determine the allocation of the adjusted Stock Purchase Price
between the classes of capital stock. After such allocation, the exercise
privilege, the number of shares issuable upon such exercise, and the Stock
Purchase Price of each class of capital stock shall thereafter be subject to
adjustment on terms comparable to those applicable to Common Stock in this
Section 3.

            (c) Such adjustment shall be made successively whenever any event
listed above shall occur.

                                        3

<PAGE>

            3.2 Adjustment for Rights Issue. If the Company distributes any
rights, options or warrants to all holders of its Common Stock entitling them at
any time after the record date mentioned below to purchase shares of Common
Stock at a price per share less than the Fair Market Value (as defined in
Section 3.4) per share of Common Stock on that record date, the Stock Purchase
Price shall be adjusted in accordance with the formula:

           E(1) = E x (O + (N x P)/M)/(O + N)

where:

          E(1) = the adjusted Stock Purchase Price.

          E    = the current Stock Purchase Price.

          O    = the number of shares of Common Stock outstanding on the record
                 date.

          N    = the number of additional shares of Common Stock issuable upon
                 exercise of the rights, options or warrants offered.

          P    = the exercise price per share of the additional shares issuable
                 upon exercise of the rights, options or warrants.

          M    = the Fair Market Value per share of Common Stock on the record
                 date.

The adjustment shall be made successively whenever any such rights, options or
warrants are issued and shall become effective immediately after the record date
for the determination of stockholders entitled to receive the rights, options or
warrants. If at the end of the period during which such rights, options or
warrants are exercisable, not all rights, options or warrants shall have been
exercised, the Stock Purchase Price shall be immediately readjusted to what it
would have been if "N" in the above formula had been the number of shares
actually issued.

            3.3 Adjustment for Other Distributions. If the Company distributes
to all holders of its Common Stock any of its assets (including but not limited
to cash and securities), the Stock Purchase Price shall be adjusted in
accordance with the formula:

            E(1) = E x (M - F)/M

where:

            E(1) = the adjusted Stock Purchase Price.

            E    = the current Stock Purchase Price.

                                        4

<PAGE>

            M = the Fair Market Value per share of Common Stock on the record
                date mentioned below.

            F = the fair market value on the record date of the assets, debt
                securities, capital stock or rights or warrants applicable to
                one share of Common Stock. The Board of Directors shall
                determine the fair market value.

The adjustment shall be made successively whenever any such distribution is made
and shall become effective immediately after the record date for the
determination of stockholders entitled to receive the distribution.

      This subsection does not apply to non-extraordinary quarterly cash
dividends distributed to all holders of Common Stock.

            3.4 Fair Market Value. As used in this Agreement, the "Fair Market
Value" per share of Common Stock on any date is (i) if the Common Stock is not
at the time of such determination publicly traded, the fair market value as
determined in good faith by the Board of Directors of the Company or (ii) if the
Common Stock is at the time of such determination publicly traded, the market
price of the Common Stock (the market price determined, for any date, as the
average of the closing prices of the Common Stock on the Nasdaq National Market
(or such other principal securities exchange or automated quotation system upon
which the Common Stock may then be listed for public trading) for the five
immediately preceding trading days on such exchange.

            3.5 When Adjustments May Be Deferred. No adjustment in the Stock
Purchase Price need be made unless the adjustment would require an increase or
decrease of at least 1% in the Stock Purchase Price. Any adjustments that are
not made shall be carried forward and taken into account in any subsequent
adjustment. All calculations under this Section shall be made to the nearest
cent or to the nearest 1/100th of a share, as the case may be.

            3.6 No Adjustment Required. No adjustment need be made for a
transaction referred to in subsections 3.1 through 3.3 if:

            (a) Warrant holders are to participate in the transaction on a basis
and with notice that the Board of Directors determines to be fair and
appropriate in light of the basis on which holders of Common Stock participate
in the transaction. Further, no adjustment need be made for rights to purchase
Common Stock pursuant to a Company plan for reinvestment of dividends or
interest; or

            (b) there is a change in the par value or no par value of the Common
Stock; or

            (c) the Company distributes or issues rights to all holders of its
Common Stock pursuant to a stockholder rights plan, provided that, upon exercise
of the Warrant, each holder thereof receives the same type and number of
unexpired rights it would have received (as adjusted for any event described in
Section 3.1 or 3.8) had it exercised its Warrant, and been a holder of the
Warrant Shares issuable upon exercise thereof, prior to the record date for such
distribution or issuance; or

                                        5

<PAGE>

            (d) the Warrant becomes convertible into cash, no adjustment need be
made thereafter as to the cash and interest will not accrue on the cash.

            3.7 Notice of Adjustment. Whenever the Stock Purchase Price is
adjusted, the Company shall provide the notices required by Section 8 hereof.

            3.8 Reorganization of Company. If any reclassification of the Common
Stock of the Company or any consolidation or merger of the Company with another
entity, or the sale or lease of all or substantially all of the Company's assets
to another entity shall be effected in such a way that holders of the Common
Stock of the Company shall be entitled to receive stock, securities or assets
with respect to or in exchange for such Common Stock, then, as a condition
precedent to such reclassification, consolidation, merger, sale or lease, lawful
and adequate provisions shall be made whereby the Warrant holder shall
thereafter have the right to purchase and receive upon the basis and the terms
and conditions specified in this Warrant and in lieu of the shares of Common
Stock immediately theretofore purchasable and receivable upon the exercise of
the rights represented hereby, such shares of stock, securities or assets as
maybe issued or payable in such reclassification, consolidation, merger, sale or
lease with respect to or in exchange for the number of shares of Common Stock
purchasable and receivable upon the exercise of the rights represented hereby
had such rights been exercised immediately prior thereto, and in any such case
appropriate provision shall be made with respect to the rights and interests of
the holders of the Warrant to the end that the provisions hereof (including
without limitation provisions for adjustments of the Stock Purchase Price and of
the number of shares of Common Stock purchasable and receivable upon the
exercise of the Warrant) shall thereafter be applicable, as nearly as may be, in
relation to any shares of stock, securities or assets thereafter deliverable
upon the exercise hereof. The Company will not effect any such reclassification,
consolidation, merger, sale or lease, unless prior to the consummation thereof
the successor corporation (if other than the Company) resulting from such
reclassification, consolidation or merger or the corporation purchasing or
leasing such assets shall assume by a supplemental Warrant Agreement, executed
and mailed or delivered to the holders of the Warrant at the last address
thereof appearing on the books of Company, the obligation to deliver to such
holders such shares of stock, securities or assets as, in accordance with the
foregoing provisions, such holders may be entitled to purchase.

            (a) If the issuer of securities deliverable upon exercise of
Warrants under the supplemental Warrant Agreement is an affiliate of the formed,
surviving, transferee or lessee corporation, that issuer shall join in the
supplemental Warrant Agreement.

            (b) If this subsection 3.8 applies, subsections 3.1 through 3.3 do
not apply.

            3.9 When Issuance or Payment May Be Deferred. In any case in which
this Section 3 shall require that an adjustment in the Stock Purchase Price be
made effective as of a record date for a specified event, the Company may elect
to defer until the occurrence of such event (i) issuing to the holder of any
Warrant exercised after such record date the Warrant Shares and other capital
stock of the Company, if any, issuable upon such exercise over and above the
Warrant Shares and other capital stock of the Company, if any, issuable upon
such exercise on the basis of the Stock Purchase Price and (ii) paying to such
holder any amount in cash in lieu of a fractional share pursuant to Section 11;
provided, however, that the Company shall deliver to

                                        6

<PAGE>

such holder a due bill or other appropriate instrument evidencing such holder's
right to receive such additional Warrant Shares, other capital stock and cash
upon the occurrence of the event requiring such adjustment.

            3.10 Adjustment in Number of Shares. Upon each adjustment of the
Stock Purchase Price pursuant to Section 3.1 or 3.2, the Warrant outstanding
prior to the making of the adjustment in the Stock Purchase Price shall
thereafter evidence the right to receive upon payment of the adjusted Stock
Purchase Price that number of shares of Common Stock (calculated to the nearest
hundredth) obtained from the following formula:

                     N(1) = N x E/E(1)

where:

            N(1) = the adjusted number of Warrant Shares issuable upon exercise
                   of a Warrant by payment of the adjusted Stock Purchase Price.

            N    = the number of Warrant Shares previously issuable upon
                   exercise of a Warrant by payment of the Stock Purchase Price
                   prior to adjustment.

            E(1) = the adjusted Stock Purchase Price.

            E    = the Stock Purchase Price prior to adjustment.

There shall be no adjustment in the number of shares of Common Stock that the
Warrant evidences the right to receive in the case of any adjustment to the
Stock Purchase Price pursuant to Section 3.3.

            3.11 Form of Warrant. Irrespective of any adjustments in the Stock
Purchase Price or the number or kind of shares purchasable upon the exercise of
the Warrant, any Warrant theretofore or thereafter issued may continue to
express the same price and number and kind of shares as are stated in the
Warrant initially issuable.

      4.    ISSUANCES AND TRANSFER TAXES.

            The issuance of certificates in the name of the Holder for the
Warrant Shares upon the exercise of this Warrant shall be made without charge to
the Holder of this Warrant for any issue tax in respect thereof. The Holder
shall pay all stock transfer taxes, if any, in respect of any transfer of this
Warrant or any Warrant Shares.

      5.    NO VOTING OR DIVIDEND RIGHTS; LIMITATION OF LIABILITY.

            Nothing contained in this Warrant shall be construed as conferring
upon the Holder hereof the right to vote or to consent or to receive notice as a
stockholder in respect of meetings of stockholders for the election of directors
of the Company or any other matters or any rights whatsoever as a stockholder of
the Company. Except for the adjustment to the Stock

                                        7

<PAGE>

Purchase Price pursuant to Section 3.1 hereof in the event of a dividend on the
Common Stock payable in shares of Common Stock, no dividends or interest shall
be payable or accrued in respect of this Warrant or the interest represented
hereby or the shares purchasable hereunder until, and only to the extent that,
this Warrant shall have been exercised.

      6.    RESTRICTIONS ON TRANSFERABILITY OF SECURITIES.

            6.1 Restrictions on Transfer of Warrant Shares. The Holder shall not
sell Warrant Shares, either under a registration statement or otherwise, until
after a 31 day period from the date of exercise of the Warrant Shares to be
sold. The Warrant Shares shall not be transferable except upon the conditions
specified in the Warrant Purchase Agreement.

            6.2 Transferees Bound by Warrant. Subject to compliance with the
other provisions of this Section 6, the Holder may sell this Warrant or the
Warrant Shares in accordance with applicable law; provided, however, that the
transferee of such security shall be bound by all the terms and provisions of
this Warrant and no sale shall be valid unless such transferee consents in
writing to be bound by the terms of this Warrant.

            6.3 Transfers in Violation of Warrant. Any sale or attempted sale of
this Warrant or the Warrant Shares in violation of any provision of this Warrant
shall be void, and the Company shall not record such sale on its books nor treat
any purported transferee of such securities as the owner of such securities for
any purpose.

      7.    MODIFICATION AND WAIVER.

            This Warrant and any provision hereof may be changed, waived,
discharged or terminated only by an instrument in writing signed by the party
against which enforcement of the same is sought.

      8.    NOTICES.

            All notices and other communications required or permitted hereunder
shall be effective upon receipt and shall be in writing and may be delivered in
person, by facsimile, overnight delivery service or U.S. mail, in which event it
may be mailed by first-class, certified or registered, postage prepaid,
addressed:

      if to the Holder, at

                      Amgen Inc.
                      One Amgen Center Drive
                      Thousand Oaks, CA 91320-1789
                      Attention: Corporate Secretary
                      Fax: (805) 447-1010

      or

                                        8

<PAGE>

      if to the Company, at

                       ViaCell, Inc.
                       245 First Street
                       Cambridge, MA 02142
                       Attention: President
                       Fax:

      with a copy to

                       Ropes & Gray LLP
                       One International Place
                       Boston, MA 02110
                       Attention: Marc A. Rubenstein
                       Fax: 617-951-7050

or in any case at such other address as the Holder or the Company shall have
furnished to the other in writing.

      9.    DESCRIPTIVE HEADINGS AND GOVERNING LAW.

            The descriptive headings of the Sections and paragraphs of this
Warrant are inserted for convenience only and do not constitute a part of this
Warrant. This Warrant shall be construed and enforced in accordance with, and
the rights of the parties shall be governed by, the laws of the State of
Delaware without regard to conflict of laws.

      10.   LOST WARRANTS OR STOCK CERTIFICATES.

            The Company represents and warrants to the Holder that upon receipt
of evidence reasonably satisfactory to the Company of the loss, theft,
destruction, or mutilation of any Warrant or stock certificate and, in the case
of any such loss, theft or destruction, upon receipt of an indemnity and, if
requested, bond reasonably satisfactory to the Company, or in the case of any
such mutilation upon surrender and cancellation of such Warrant or stock
certificate, the Company at its expense will make and deliver a new Warrant or
stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or
mutilated Warrant or stock certificate.

      11.   FRACTIONAL SHARES.

            No fractional shares shall be issued upon exercise of this Warrant.
The Company shall, in lieu of issuing any fractional share, pay the Holder
entitled to such fraction a sum in cash equal to such fraction multiplied by (i)
if the Common Stock is not at the time of such determination publicly traded,
the fair market value as determined in good faith by the Board of Directors of
the Company or (ii) if the Common Stock is at the time of such determination
publicly traded, the market price of the Common Stock (the market price
determined, for any date, as the average of the closing prices of the Common
Stock on the Nasdaq National Market (or such other principal securities exchange
or automated quotation system upon which the Common Stock may then be listed for
public trading) for the five immediately preceding trading days on such
exchange).

                                        9

<PAGE>

      12.   NO IMPAIRMENT.

            The Company will not, by amendment of its Certificate of
Incorporation or bylaws, or through reorganization, consolidation, merger,
dissolution, issue or sale of securities, sale of assets or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out
of all such terms and in the taking of all such action as may be necessary or
appropriate in order to protect the rights of the Holder of this Warrant against
impairment. Without limiting the generality of the foregoing, the Company (a)
will not increase the par value of any shares of stock issuable upon the
exercise of this Warrant above the amount payable therefor upon such exercise,
and (b) will take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and non-assessable
shares of Common Stock upon exercise of this Warrant.

                                       10

<PAGE>

      IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by
its officers, thereunto duly authorized this 29th day of August, 2005.

                                         VIACELL, INC.

                                         /s/ Marc D. Beer
                                         -----------------------------
                                         By: Marc D. Beer
                                         Title: Chief Executive Officer

                           [Signature Page to Warrant]<PAGE>
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS
([**]), HAS BEEN OMITTED AND FILED SEPARATELY WTH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED

                           EXCLUSIVE LICENSE AGREEMENT

                                      AMONG

                          THE JOHNS HOPKINS UNIVERSITY

                                        &

                               ZHEJIANG UNIVERSITY

                                        &

                                  VIACELL, INC.

                               JHU REF. NO.: 4664

<PAGE>

                                                                    EXHIBIT 10.4

                                LICENSE AGREEMENT

     THIS LICENSE AGREEMENT (the "Agreement") is entered into by and among The
Johns Hopkins University, a Maryland corporation having an address at 3400 N.
Charles Street, Baltimore, Maryland, 21218-2695 (hereinafter referred to as
"JHU"), Zhejiang University having an address at 232 Wen San Road, Hangzhou,
Zhejiang 310012., P.R. China (hereinafter referred to as "INSTITUTION") (both
hereinafter collectively referred to as "LICENSORS"), and ViaCell, Inc., a
Delaware corporation, having an address at 245 First Street, 15th Floor,
Cambridge, MA 02142 (hereinafter referred to as "COMPANY") (JHU, INSTITUTION,
and COMPANY are hereinafter collectively referred to as the "Parties"), with
respect to the following:

                                    RECITALS

     WHEREAS, as centers for research and education, JHU and INSTITUTION are
interested in licensing PATENT RIGHTS (hereinafter defined) in a manner that
will benefit the public by facilitating the distribution of useful products and
the utilization of new processes, but are without capacity to commercially
develop, manufacture, and distribute any such products or processes; and

     WHEREAS, a valuable invention(s) entitled [**] was developed during the
course of research conducted by Dr. Ian McNiece, a faculty member at JHU, and
Dr. Jinfu Wang, a faculty member at INSTITUTION (hereinafter collectively
referred to as "Inventors"); and

     WHEREAS, LICENSORS have acquired through assignment all rights, title and
interest, with the exception of certain retained rights by the United States
Government, in their interest in said valuable inventions; and

     WHEREAS, LICENSORS agreed that JHU will take the lead with respect to
commercializing said inventions in accordance with the terms of the
Interinstitutional Agreement between JHU and INSTITUTION effective as of May
16th, 2005; and

     WHEREAS, COMPANY has informed LICENSORS, in accordance with the terms of
the Option Agreement effective as of May 16th, 2005, that it desires to acquire
certain rights in such inventions as herein provided, and to commercially
develop, manufacture, use and distribute products and processes based upon or
embodying said valuable inventions;

     NOW THEREFORE, in consideration of the premises and the mutual promises and
covenants contained in this Agreement, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
Parties hereto agree as follows:

                                                                             -2-

<PAGE>

                                                                    EXHIBIT 10.4

                                    ARTICLE 1
                                   DEFINITIONS

     All references to particular Exhibits, Articles or Paragraphs shall mean
the Exhibits to, and Paragraphs and Articles of, this Agreement, unless
otherwise specified. For the purposes of this Agreement and the Exhibits hereto,
the following words and phrases shall have the following meanings:

     1.1 "AFFILIATED COMPANY" as used herein in either singular or plural shall
mean any corporation, company, partnership, joint venture or other entity, which
controls, is controlled by or is under common control with COMPANY. For purposes
of this Paragraph 1.1, control shall mean the direct or indirect ownership of at
least fifty- percent (50%) of the voting or economic interest in said entity.

     1.2 "DEVELOPED PRODUCT(S)" as used herein in either singular or plural
shall mean any materials, compositions, drugs, other products, methods or
services which are in material part first identified, discovered or made by
practicing one or more VALID CLAIMS in the PATENT RIGHTS licensed hereunder.
DEVELOPED PRODUCT(S) shall include all resultant FDA and other regulatory agency
approved products identified by COMPANY which are in material part made or
discovered through the use of the PATENT RIGHTS delivered hereunder. DEVELOPED
PRODUCT(S) excludes LICENSED PRODUCT(S) and LICENSED SERVICE(S).

     1.3 "DEVELOPED PRODUCT LICENSEE(S)" as used herein in either singular or
plural shall mean any person or entity other than AFFILIATED COMPANIE(S) to
which COMPANY has granted a license to DEVELOPED PRODUCT(S).

     1.4 "EFFECTIVE DATE" of this License Agreement shall mean the date the last
Party hereto has executed this Agreement.

     1.5 "EXCLUSIVE LICENSE" shall mean a grant by LICENSORS to COMPANY of their
entire right and interest in the PATENT RIGHTS subject to rights retained by the
United States Government, if any, in accordance with the Bayh-Dole Act of 1980
(established by P.L. 96-517 and amended by P.L. 98-620, codified at 35 USC
Section 200 et. seq. and implemented according to 37 CFR Part 401), and subject
to the retained right of LICENSORS to make, have made, provide and use for their
and The Johns Hopkins Health Systems' non-commercial purposes PATENT RIGHTS,
LICENSED PRODUCT(S) and LICENSED SERVICE(S), including the ability to distribute
any biological material, including, but not limited to, material disclosed
and/or claimed in PATENT RIGHTS, for nonprofit academic research use to
non-commercial entities, as is customary in the scientific community.

     1.6 "KNOW HOW" shall mean any unpatented technical information, research
data, designs, formulas, process information, clinical data and other
information which is owned by LICENSORS and directly related to PATENT RIGHTS
licensed hereunder and generated in the laboratories of Dr. Ian McNiece and Dr.
Jinfu Wang prior to the EFFECTIVE DATE and which

                                                                             -3-

<PAGE>

                                                                    EXHIBIT 10.4

LICENSORS have the right to license, necessary for the exercise or use of the
PATENT RIGHTS in the LICENSED FIELD.

     1.7 "LICENSED FIELD" shall mean [**].

     1.8 "LICENSED PRODUCT(S)" as used herein in either singular or plural shall
mean any process or method, material, compositions, drug, or other product, the
manufacture, use or sale of which would constitute, but for the license granted
to COMPANY pursuant to this Agreement, an infringement of a VALID CLAIM of
PATENT RIGHTS (infringement shall include, but is not limited to, direct,
contributory, or inducement to infringe).

     1.9 "LICENSED SERVICE(S)" as used herein in either singular or plural shall
mean the performance on behalf of a third party of any method or service or the
manufacture of any product or the use of any product or composition which would
constitute, but for the license granted to COMPANY pursuant to this Agreement,
an infringement of a VALID CLAIM of the PATENT RIGHTS, (infringement shall
include, but not be limited to, direct, contributory or inducement to infringe).

     1.10 "NET SALES" shall mean gross sales revenues and fees billed by
COMPANY, AFFILIATED COMPANY, SUBLICENSEE(S) and/or DEVELOPED PRODUCT LICENSEE(S)
from the sale or other disposition of LICENSED PRODUCT(S) or DEVELOPED
PRODUCT(S), less reasonable (and, in each every case, actually paid or applied)
trade discounts allowed, refunds, returns and recalls, and sales taxes directly
related to the sale or delivery of LICENSED PRODUCT(S) and/or DEVELOPED
PRODUCT(S).

          In the event that COMPANY, AFFILIATED COMPANY, SUBLICENSEE(S) and/or
DEVELOPED PRODUCT LICENSEE(S) sells a LICENSED PRODUCT(S) and/or DEVELOPED
PRODUCT(S) in combination with other ingredients or substances which are not
LICENSED PRODUCTS, LICENSED SERVICE(S) or DEVELOPED PRODUCT(S) ("Other Items")
or as part of a kit that contains Other Items, the NET SALES shall mean the
amount billed by COMPANY, AFFILIATED COMPANY, SUBLICENSEE(S) and/or DEVELOPED
PRODUCT LICENSEE(S) on sales of the combination process or product less the
deductions set forth above, multiplied by a proration factor determined as
follows:

     (a) If all LICENSED PRODUCT(S) or DEVELOPED PRODUCT(S) and Other Items were
     sold separately during the same or immediately preceding year, the
     proration factor shall be determined by the formula [A / (A+B)], where A is
     the aggregate gross sales price of all LICENSED PRODUCT(S) and/or DEVELOPED
     PRODUCT(S) components during such period when sold separately from the
     Other Items, and B is the aggregate gross sales price of all Other Items
     during such period when sold separately from the LICENSED PRODUCT(S) and/or
     DEVELOPED PRODUCT(S) components; or

                                                                             -4-

<PAGE>

                                                                    EXHIBIT 10.4

     (b) If the combination includes Other Items which are not sold separately
     (but all LICENSED PRODUCT(S) and/or DEVELOPED PRODUCT(S) in the combination
     are available separately), the NET SALES for purposes of royalty payments
     will be calculated by multiplying the NET SALES of the combination by A/C,
     where A is defined above and C is the invoiced price of the combination.

     (c) If all components of the combination process or product were not sold
     separately during the same or immediately preceding year, the proration
     factor shall be determined by the formula [C / (C+D)], where C is the value
     of the LICENSED PRODUCT(S) and/or DEVELOPED PRODUCT(S) components and D is
     the value of the Other Items, with such value being determined in good
     faith by the parties.

     The term "Other Items" does not include solvents, diluents, carriers,
     excipients, buffers or the like used in formulating a product, or other
     non-essential components required in a process or service.

     1.11 "NET SERVICE REVENUES" shall mean gross service revenues and fees
billed by COMPANY, AFFILIATED COMPANY, SUBLICENSEE(S) and/or DEVELOPED PRODUCT
LICENSEE(S) for or in connection with the performance of LICENSED SERVICE(S)
and/or DEVELOPED PRODUCT(S) less reasonable and appropriate (and, in each every
case, actually paid or applied) trade discounts allowed, refunds, returns and
recalls, duties and sales and/or use taxes imposed upon and directly related to
the sale of or fee the LICENSED SERVICE(S) and/or DEVELOPED PRODUCT(S). In the
event that COMPANY, AFFILIATED COMPANY, SUBLICENSEE(S) and/or DEVELOPED PRODUCT
LICENSEE(S) sells a LICENSED SERVICE(S) and/or DEVELOPED PRODUCT(S) in
combination with Other Items or as part of a kit that contains Other Items, the
NET SERVICE REVENUES for purposes of royalty payments shall mean the amount
billed by COMPANY, AFFILIATED COMPANY, SUBLICENSEE(S) and/or DEVELOPED PRODUCT
LICENSEE(S) on sales of the combination process, service or product less the
deductions set forth above, multiplied by a proration factor determined as
follows:

     (a) If all LICENSED SERVICE(S) and/or DEVELOPED PRODUCT(S) and Other Items
     were sold separately during the same or immediately preceding year, the
     proration factor shall be determined by the formula [A / (A+B)], where A is
     the aggregate gross sales price of all LICENSED SERVICE(S) and/or DEVELOPED
     PRODUCT(S) components during such period when sold separately from the
     Other

                                                                             -5-

<PAGE>

                                                                    EXHIBIT 10.4

     Items, and B is the aggregate gross sales price of the Other Items during
     such period when sold separately from the LICENSED SERVICE(S) and/or
     DEVELOPED PRODUCT(S) components; or

     (b)If the combination includes Other Items which are not sold separately
     (but all LICENSED SERVICE(S) and/or DEVELOPED PRODUCT(S) in the combination
     are available separately), the NET SERVICE REVENUES for purposes of royalty
     payments will be calculated by multiplying the NET SERVICE REVENUE of the
     combination by A/C, where A is defined above and C is the invoiced price of
     the combination.

     (c) If all components of the combination process, service or product were
     not sold separately during the same or immediately preceding year, the
     proration factor shall be determined by the formula [C / (C+D)], where C is
     the value of the LICENSED SERVICE(S) and/or DEVELOPED PRODUCT(S) components
     and D is the value of the Other Items, with such value being determined in
     good faith by the parties.

     1.12 "PATENT RIGHTS" shall mean [**].

     1.13 "SUBLICENSEE(S)" as used herein in either singular or plural shall
mean any person or entity other than an AFFILIATED COMPANY to which COMPANY has
granted a sublicense under this Agreement.

     1.14 "VALID CLAIM(S)" as used herein in either singular or plural shall
mean any unexpired issued claim or pending claim prosecuted in good faith of any
PATENT RIGHTS that has not been (i) finally rejected, (ii) declared invalid or
unenforceable by a patent office or court of competent jurisdiction in any
unappealed and unappealable decision or (iii) admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise by the holder thereof.

                                    ARTICLE 2
                                  LICENSE GRANT

     2.1 GRANT. Subject to the terms and conditions of this Agreement, LICENSORS
hereby grant to COMPANY (i) an EXCLUSIVE LICENSE to develop, make, have made,
use, import, offer for sale and sell the LICENSED PRODUCT(S) and DEVELOPED
PRODUCT(S), and to provide the LICENSED SERVICE(S) under the PATENT RIGHTS in
the LICENSED FIELD; and (ii) a non exclusive license to use KNOW HOW for
COMPANY'S internal research purposes only to develop and manufacture LICENSED
PRODUCT(S), LICENSEND SERVICE(S) and DEVELOPED PRODUCT(S) in the LICENSED FIELD.
These Grants shall apply to the COMPANY and any AFFILIATED COMPANY. If any
AFFILIATED COMPANY exercises rights under this Agreement, such AFFILIATED
COMPANY shall be bound by all terms and royalty payments, which shall apply to
the exercise of the rights, to the same extent as would apply

                                                                             -6-

<PAGE>

                                                                    EXHIBIT 10.4

had this Agreement been directly between LICENSORS and the AFFILIATED COMPANY.
In addition, COMPANY shall remain fully liable to LICENSORS for all acts and
obligations of AFFILIATED COMPANY such that acts of the AFFILIATED COMPANY shall
be considered acts of the COMPANY.

     2.2 SUBLICENSE. COMPANY may sublicense others under this Agreement, subject
to the terms and conditions of this Paragraph. As a condition to its validity
and enforceability, each sublicense agreement shall: (a) incorporate by
reference the terms and conditions of this Agreement, (b) be consistent with the
terms, conditions and limitations of this Agreement, (c) prohibit SUBLICENSEE'S
further sublicense of the rights delivered hereunder, (d) name LICENSORS as
intended third party beneficiaries of the obligations of SUBLICENSEE without
imposition of obligation or liability on the part of LICENSORS or their
Inventors to the SUBLICENSEE, (e) specifically incorporate Paragraphs 6.2
"Representations by LICENSORS", 7.1 "Indemnification", 10.1 "Use of Name", 10.4
"Product Liability" into the body of the sublicense agreement, and cause the
terms used therein to have the same meaning as in this Agreement. JHU shall have
the right to review all such sublicenses prior to execution for period of ten
(10) days (the "Review Period") of receipt of the sublicense from COMPANY to
confirm that the sublicense contains the provisions referenced above.
Notwithstanding the foregoing, although COMPANY will not enter into any
Sublicense prior to the expiration of the Review Period, COMPANY's right to
grant sublicenses under the PATENT RIGHTS shall not be contingent upon COMPANY's
receipt of JHU's prior approval. COMPANY agrees to provide JHU with a copy of
each executed sublicense agreement promptly upon its execution (and in any event
within ten (10) days thereafter). To the extent that any terms, conditions or
limitations of any sublicense agreement are inconsistent with this Agreement,
those terms, conditions and limitations are null and void against LICENSORS.

     2.3 GOVERNMENT RIGHTS. The United States Government may have acquired a
nonexclusive, nontransferable, irrevocable, paid-up license to practice or have
practiced for or on behalf of the United States the inventions described in
PATENT RIGHTS throughout the world. The rights granted herein are additionally
subject to: (i) the requirement that any LICENSED PRODUCT(S) produced for use or
sale within the United States shall be substantially manufactured in the United
States (unless a waiver under 35 USC Section 204 or equivalent is granted by the
appropriate United States government agency), (ii) the right of the United
States government to require JHU, or its licensees, including COMPANY, to grant
sublicenses to responsible applicants on reasonable terms when necessary to
fulfill health or safety needs, and, (iii) other rights acquired by the United
States government under the laws and regulations applicable to the
grant/contract award under which the inventions were made.

                                                                             -7-

<PAGE>

                                                                    EXHIBIT 10.4

                                    ARTICLE 3
                           FEES, ROYALTIES, & PAYMENTS

     3.1 LICENSE FEE. COMPANY shall pay to JHU within thirty (30) days of the
EFFECTIVE DATE of this Agreement a license fee as set forth in Exhibit A. JHU
will not submit an invoice for the license fee, which is nonrefundable and shall
not be credited against royalties or other fees.

     It is agreed an understood that if this Agreement is terminated prior to
January 1st, 2006, COMPANY will pay to JHU, without invoice from JHU, within ten
(10) business days following the termination date of this Agreement, [**].
Otherwise, this amount is due as indicated in paragraph 3.2.

     3.2 MINIMUM ANNUAL ROYALTIES. COMPANY shall pay to JHU minimum annual
royalties as set forth in Exhibit A. These minimum annual royalties shall be
due, without invoice from JHU, as applicable, either within thirty (30) days of
the date indicated or each anniversary of the EFFECTIVE DATE, beginning with the
first anniversary. Running royalties accrued under Paragraph 3.3 and paid to JHU
during the one year period preceding an anniversary of the EFFECTIVE DATE shall
be credited against the minimum annual royalties due on that anniversary date.

     3.3 RUNNING ROYALTIES. COMPANY shall pay to JHU a running royalty as set
forth in Exhibit A, for each LICENSED PRODUCT(S) sold, for each LICENSED
SERVICE(S) provided, and for each DEVELOPED PRODUCT(S) sold or provided, by
COMPANY, AFFILIATED COMPANIES, SUBLICENSEE(S), and/or DEVELOPED PRODUCT
LICENSEE(S) based on NET SALES and NET SERVICE REVENUES for the term of this
Agreement. Such payments shall be made quarterly. [**].

     (a) In order to insure JHU the full royalty payments contemplated
hereunder, COMPANY agrees that in the event any LICENSED PRODUCT(S) or DEVELOPED
PRODUCT(S) shall be sold to an AFFILIATED COMPANY, SUBLICENSEE(S) and/or
DEVELOPED PRODUCT LICENSEE(S) or to a corporation, firm or association with
which COMPANY shall have any agreement, understanding or arrangement with
respect to consideration (such as, among other things, an option to purchase
stock or actual stock ownership, or an arrangement involving division of profits
or special rebates or allowances) the royalties to be paid hereunder for such
LICENSED PRODUCT(S) or DEVELOPED PRODUCT(S) shall be based upon the greater of:
[**].

     (b) COMPANY acknowledges that its agreement to make payments to LICENSORS
under this Paragraph regarding rights, products and/or services that are not:
(i) included in PATENT RIGHTS, or, (ii) a LICENSED PRODUCT(S) or LICENSED
SERVICE(S), has been made for purposes of its own convenience, to be paid
hereunder in lieu of other payments as might have otherwise been required to be
paid for the license of the rights delivered hereunder.

     3.4 SUBLICENSE CONSIDERATION. In addition to the running royalty as set
forth under Paragraph 3.3, COMPANY shall pay to JHU a percentage of
consideration received for sublicenses

                                                                             -8-

<PAGE>

                                                                    EXHIBIT 10.4

under this Agreement as set forth in Exhibit A. This sublicense consideration
shall be due, without the need for invoice from JHU, within forty-five (45) days
of COMPANY's receipt of consideration from SUBLICENSEE(S). Such consideration
shall mean consideration of any kind received by the COMPANY or AFFILIATED
COMPANIES from a SUBLICENSEE(S) and/or DEVELOPED PRODUCT LICENSEE(S) for the
grant of a sublicense under this Agreement including transactions related to the
development and manufacture of DEVELOPED PRODUCT(S), such as upfront fees or
milestone fees and including any premium paid by the SUBLICENSEE(S) and/or
DEVELOPED PRODUCT LICENSEE(S) over Fair Market Value for stock of the COMPANY or
an AFFILIATED COMPANY in consideration for such sublicense. However, not
included in such sublicense consideration are amounts paid to the COMPANY or an
AFFILIATED COMPANY for running royalties on LICENSED PRODUCT(S), LICENSED
SERVICE(S) and DEVELOPED PRODUCT(S), profit sharing or other consideration based
on the level of NET SALES or profits, or bona fide support for product
development, research work, clinical studies, reimbursement for patent costs,
and regulatory approvals performed by or for the COMPANY or AFFILIATED COMPANIES
(including third parties on their behalf), each pursuant to a specific
agreement. The term "Fair Market Value" shall mean the average price that the
stock in question is publicly trading at for twenty (20) days prior to the
announcement of its purchase by the SUBLICENSEE(S) or DEVELOPED PRODUCT
LICENSEE(S) or if the stock is not publicly traded, the value of such stock to
be reasonably determined by BOTH PARTIES .

     3.5 MILESTONE PAYMENTS. COMPANY shall pay to JHU, without invoice from JHU,
the milestone payments as set forth in Exhibit A. These milestone payments shall
not be deducted from royalty or other payments due to JHU.

     3.6 PATENT REIMBURSEMENT. COMPANY will reimburse JHU, within thirty (30)
days of the receipt of an invoice from JHU, for all costs associated with the
preparation, filing, maintenance, and prosecution of PATENT RIGHTS incurred by
LICENSORS on or before the EFFECTIVE DATE of this Agreement. In accordance with
Paragraph 4.1 below, COMPANY will reimburse JHU, within thirty (30) days of the
receipt of an invoice from JHU, for all costs associated with the preparation,
filing, maintenance, and prosecution of PATENT RIGHTS incurred by LICENSORS
subsequent to the EFFECTIVE DATE of this Agreement.

     3.7 FORM OF PAYMENT. All payments under this Agreement shall be made in
U.S. Dollars. Checks are to be made payable to "The Johns Hopkins University".
Wire transfers may be made through:

          Bank of America
          New York, NY

          [**]

     COMPANY shall be responsible for any and all costs associated with wire
transfers.

     3.8 LATE PAYMENTS. In the event that any payment due hereunder is not made
when due, the payment shall accrue interest beginning on the tenth day following
the due date thereof, calculated at the annual rate of the sum of [**]. Each
such payment when made shall be

                                                                             -9-

<PAGE>

                                                                    EXHIBIT 10.4

accompanied by all interest so accrued. Said interest and the payment and
acceptance thereof shall not negate or waive the right of JHU to seek any other
remedy, legal or equitable, to which it may be entitled because of the
delinquency of any payment including, but not limited to termination of this
Agreement as set forth in Paragraph 9.2.

                                    ARTICLE 4
                 PATENT PROSECUTION, MAINTENANCE, & INFRINGEMENT

     4.1 PROSECUTION & MAINTENANCE. JHU, at COMPANY'S expense as provided in
Section 3.6, shall file, prepare, prosecute and maintain all patents and patent
applications specified under PATENT RIGHTS and, subject to the terms and
conditions of this Agreement, COMPANY shall be licensed thereunder. Title to all
such patents and patent applications shall reside in LICENSORS. LICENSORS shall
have full and complete control over all patent matters in connection therewith
under the PATENT RIGHTS, provided however, that JHU shall (a) cause its patent
counsel to timely copy COMPANY on all official actions and written
correspondence with, and received from, any patent office, and (b) allow COMPANY
a reasonable opportunity to comment and advise JHU on all filings and
communications to be made with any patent office. LICENSORS shall consider and
reasonably incorporate all comments and advice. By concurrent written
notification to JHU and its patent counsel at least thirty (30) days in advance
(or later at JHU's discretion) of any filing or response deadline, or fee due
date, COMPANY may elect not to have a patent application filed in any particular
country or not to pay expenses associated with prosecuting or maintaining any
patent application or patent, provided that COMPANY pays for all costs incurred
up to JHU's receipt of such notification. Failure to provide such notification
can be considered by JHU to be COMPANY'S authorization to proceed at COMPANY'S
expense. Upon such notification, LICENSORS may file, prosecute, and/or maintain
such patent applications or patent at their own expense and for their own
benefit, and any rights or license granted hereunder held by COMPANY, AFFILIATED
COMPANIES or SUBLICENSEE(S) relating to the PATENT RIGHTS which comprise the
subject of such patent applications or patent and/or apply to the particular
country, shall terminate.

     4.2 NOTIFICATION. Each Party will notify the other promptly in writing when
any infringement by another is uncovered or suspected.

     4.3 INFRINGEMENT. COMPANY shall have the first right to enforce any patent
within PATENT RIGHTS against any infringement or alleged infringement thereof,
and shall at all times keep JHU informed as to the status thereof. Before
COMPANY commences an action with respect to any infringement of such patents,
COMPANY shall give careful consideration to the views of LICENSORS and to
potential effects on the public interest in making its decision whether or not
to sue. Thereafter, COMPANY may, at its own expense, institute suit against any
such infringer or alleged infringer and control and defend such suit in a manner
consistent with the terms and provisions hereof and recover any damages, awards
or settlements resulting therefrom, subject to Paragraph 4.5. However, no
settlement, consent judgment or other voluntary final disposition of the suit
may be entered into without the prior written consent of LICENSORS, which
consent shall not be unreasonably withheld. This right to sue for infringement
shall not be used in an arbitrary or

                                                                            -10-

<PAGE>

                                                                    EXHIBIT 10.4

capricious manner. LICENSORS shall reasonably cooperate in any such litigation
at COMPANY'S expense.

If COMPANY elects not to enforce any patent within the PATENT RIGHTS, then it
shall so notify JHU in writing within ninety (90) days of receiving notice that
an infringement exists, and LICENSORS may, in their sole judgment and at their
own expense, take steps to enforce any patent and control, settle, and defend
such suit in a manner consistent with the terms and provisions hereof, and
recover, for their own account, any damages, awards or settlements resulting
therefrom.

     4.4 PATENT INVALIDITY SUIT. If a declaratory judgment action is brought
naming COMPANY as a defendant and alleging invalidity of any of the PATENT
RIGHTS, LICENSORS may elect to take over the sole defense of the action at their
own expense. COMPANY shall cooperate fully with LICENSORS in connection with any
such action. In the event that LICENSORS choose not to take over the sole
defense of the action at their own expense, COMPANY may elect to take over the
sole defense of the action at its own expense. However, no settlement, consent
judgment or other voluntary final disposition of the suit may be entered into
without the prior written consent of LICENSORS, which consent shall not be
unreasonably withheld.

     4.5 RECOVERY. Any recovery by COMPANY under Paragraph 4.3 shall be deemed
to reflect loss of commercial sales, and COMPANY shall pay to JHU [**].

                                    ARTICLE 5
                           OBLIGATIONS OF THE PARTIES

     5.1 REPORTS. COMPANY shall provide to JHU the following written reports
according to the following schedules.

     (a) Upon first commercial sale, COMPANY shall provide quarterly Royalty
Reports, substantially in the format of Exhibit B and due within thirty (30)
days of the end of each calendar quarter. Royalty Reports shall disclose the
amount of LICENSED PRODUCT(S), LICENSED SERVICE(S) and DEVELOPED PRODUCT(S)
sold, the total NET SALES and NET SERVICE REVENUES of such LICENSED PRODUCT(S),
LICENSED SERVICE(S) and DEVELOPED PRODUCT(S), and the running royalties due to
JHU as a result of NET SALES and NET SERVICE REVENUES by COMPANY, AFFILIATED
COMPANIES, SUBLICENSEE(S), and DEVELOPED PRODUCT LICENSEE(S) thereof. Payment of
any such royalties due shall accompany such Royalty Reports.

     (b) Until COMPANY, an AFFILIATED COMPANY, a SUBLICENSEE(S), or a DEVELOPED
PRODUCT LICENSEE(S) has achieved a first commercial sale of a LICENSED PRODUCT,
LICENSED SERVICE or DEVELOPED PRODUCT, or received FDA market approval, COMPANY
shall provide semiannual Diligence Reports, due within thirty (30) days of the
end of every June and December following the EFFECTIVE DATE of this Agreement.
These Diligence Reports shall describe COMPANY'S, AFFILIATED COMPANIES,
SUBLICENSEE(S)'S or any DEVELOPED PRODUCT LICENSEE(S) technical efforts towards
meeting its obligations under the terms of this Agreement.

                                                                            -11-

<PAGE>

                                                                    EXHIBIT 10.4

     (c) COMPANY shall provide Annual Reports within thirty (30) days of the end
of every December following the EFFECTIVE DATE of this Agreement. Annual Reports
shall include:

          (i) evidence of insurance as required under Paragraph 10.4, or, a
          statement of why such insurance is not currently required; and

          (ii) identification of all AFFILIATED COMPANIES which have exercised
          rights pursuant to Paragraph 2.1, or, a statement that no AFFILIATED
          COMPANY has exercised such rights; and

          (iii) notice of all FDA approvals of any LICENSED PRODUCT(S), LICENSED
          SERVICE(S) or DEVELOPED PRODUCT(S) obtained by COMPANY, AFFILIATED
          COMPANY, SUBLICENSEE, or DEVELOPED PRODUCT LICENSEE the patent(s) or
          patent application(s) licensed under this Agreement upon which such
          product or service is based, and the commercial name of such product
          or service, or, in the alternative, a statement that no FDA approvals
          have been obtained.

     5.2 RECORDS. COMPANY shall make and retain, for a period of [**] years
following the period of each report required by Paragraph 5.1, true and accurate
records, files and books of account containing all the data reasonably required
for the full computation and verification of sales and other information
required in Paragraph 5.1. Such books and records shall be in accordance with
generally accepted accounting principles consistently applied. COMPANY shall
permit the inspection and copying of such records, files and books of account by
JHU or its agents during regular business hours upon ten (10) business days'
written notice to COMPANY. Such inspection shall not be made more than once each
calendar year. All costs of such inspection and copying shall be paid by
LICENSORS, provided that if any such inspection shall reveal that an error has
been made in the amount equal to [**] or more of such payment, such costs shall
be borne by COMPANY. As a condition to entering into any such agreement, COMPANY
shall include in any agreement with its AFFILIATED COMPANIES, its
SUBLICENSEE(S), or DEVELOPED PRODUCT LICENSEE(S) which permits such party to
make, use, sell or import the LICENSED PRODUCT(S) or DEVELOPED PRODUCT(S) or
provide LICENSED SERVICE(S), a provision requiring such party to retain records
of sales of LICENSED PRODUCT(S), DEVELOPED PRODUCT(S) and records of LICENSED
SERVICE(S) and other information as required in Paragraph 5.1 and permit JHU to
inspect such records as required by this Paragraph.

     5.3 COMMERCIALLY REASONABLE. COMPANY shall exercise commercially reasonable
efforts to develop and to introduce the LICENSED PRODUCT(S), LICENSED SERVICE(S)
or DEVELOPED PRODUCT(S) into the commercial market as soon as practicable,
consistent with sound and reasonable business practice and judgment; thereafter,
until the expiration or termination of this Agreement, COMPANY shall endeavor to
keep LICENSED PRODUCT(S), LICENSED SERVICE(S) and DEVELOPED PRODUCT(S)
commercially reasonably available to the public. COMPANY shall also exercise
commercially reasonable efforts to develop LICENSED PRODUCT(S) suitable for
different indications within the LICENSED FIELD, so that the PATENT RIGHTS can
be commercialized as broadly and as speedily as good scientific and business
judgment would deem possible.

     5.4 OTHER PRODUCTS. After clinical or other evidence, provided in writing
by LICENSORS or by another party, to COMPANY, demonstrating the practicality of
a particular market or use within the LICENSED FIELD which is not being
developed or commercialized by

                                                                            -12-

<PAGE>

                                                                    EXHIBIT 10.4

COMPANY, COMPANY shall either provide JHU with a reasonable development plan and
start development or attempt to reasonably sublicense the particular market or
use to a third party. If within six (6) months of such notification by JHU,
COMPANY has not initiated such development efforts or sublicensed that
particular market or use, LICENSORS may terminate this license for such
particular market or use. This Paragraph shall not be applicable if COMPANY
reasonably demonstrates to LICENSORS that commercializing such LICENSED
PRODUCT(S) or LICENSED SERVICE(S) or granting such a sublicense in said market
or use would have a potentially adverse commercial effect upon marketing or
sales of the LICENSED PRODUCT(S) developed or being sold by COMPANY.

     5.5 PATENT ACKNOWLEDGEMENT. COMPANY agrees that all packaging containing
individual LICENSED PRODUCT(S) sold by COMPANY, AFFILIATED COMPANIES and
SUBLICENSEE(S) of COMPANY will be marked with the number of the applicable
patent(s) licensed hereunder in accordance with each country's patent laws.

                                    ARTICLE 6
                                 REPRESENTATIONS

     6.1 DUTIES OF THE PARTIES. LICENSORS are not a commercial organizations.
They are institutes of research and education. Therefore, LICENSORS have no
ability to evaluate the commercial potential of any PATENT RIGHTS, LICENSED
PRODUCT, DEVELOPED PRODUCT or other license or rights granted in this Agreement.
It is therefore incumbent upon COMPANY to evaluate the rights and products in
question, to examine the materials and information provided by LICENSORS, and to
determine for itself the validity of any PATENT RIGHTS, its freedom to operate,
and the value of any LICENSED PRODUCT(S) or LICENSED SERVICE(S) or other rights
granted.

     6.2 REPRESENTATIONS BY LICENSORS. LICENSORS warrant that they have good and
marketable title to their interest in the invention(s) claimed under PATENT
RIGHTS with the exception of certain retained rights of the United States
Government, which may apply if any part of the JHU research was funded in whole
or in part by the United States Government. LICENSORS do not warrant the
validity of any patents or that practice under such patents or use of such
material shall be free of infringement. EXCEPT AS EXPRESSLY SET FORTH IN THIS
PARAGRAPH 6.2, COMPANY, AFFILIATED COMPANIES AND SUBLICENSEE(S) AGREE THAT THE
PATENT RIGHTS ARE PROVIDED "AS IS", AND THAT LICENSORS MAKE NO REPRESENTATION OR
WARRANTY WITH RESPECT TO THE PERFORMANCE OF LICENSED PRODUCT(S), LICENSED
SERVICE(S) AND DEVELOPED PRODUCT(S) INCLUDING THEIR SAFETY, EFFECTIVENESS, OR
COMMERCIAL VIABILITY, OR WITH RESPECT TO THEIR UTILITY IN MAKING A DEVELOPED
PRODUCT(S) OR THE USEFULNESS OF SUCH A DEVELOPED PRODUCT(S). LICENSORS DISCLAIM
ALL WARRANTIES WITH REGARD TO PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS
AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESSED OR IMPLIED,
OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE. NOTWITHSTANDING ANY
OTHER PROVISION OF THIS

                                                                            -13-

<PAGE>

                                                                    EXHIBIT 10.4

AGREEMENT, LICENSORS ADDITIONALLY DISCLAIM ALL OBLIGATIONS AND LIABILITIES ON
THE PART OF LICENSORS AND INVENTORS, FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO,
DIRECT, INDIRECT, SPECIAL, AND CONSEQUENTIAL DAMAGES, ATTORNEYS' AND EXPERTS'
FEES, AND COURT COSTS (EVEN IF LICENSORS HAVE BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THE
MANUFACTURE, USE, OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS
AGREEMENT. COMPANY, AFFILIATED COMPANIES, SUBLICENSEE(S) AND DEVELOPED PRODUCT
LICENSEES ASSUME ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A
PRODUCT AND/OR SERVICE MANUFACTURED, USED, OR SOLD BY COMPANY, ITS
SUBLICENSEE(S), DEVELOPED PRODUCT LICENSEE(S) AND AFFILIATED COMPANIES WHICH IS
A LICENSED PRODUCT(S), LICENSED SERVICE(S) OR DEVELOPED PRODUCT(S) AS DEFINED IN
THIS AGREEMENT.

                                    ARTICLE 7
                                 INDEMNIFICATION

     7.1 INDEMNIFICATION. LICENSORS and the Inventors will have no legal
liability exposure to third parties if LICENSORS do not license the LICENSED
PRODUCT(S) and LICENSED SERVICE(S), and any royalties LICENSORS and the
Inventors may receive is not adequate compensation for such legal liability
exposure. Therefore, LICENSORS require COMPANY to protect LICENSORS and
Inventors from such exposure to the same manner and extent to which insurance,
if available, would protect LICENSORS and Inventors. Furthermore, LICENSORS and
the Inventors will not, under the provisions of this Agreement or otherwise,
have control over the manner in which COMPANY or its AFFILIATED COMPANIES or its
SUBLICENSEE(S), or DEVELOPED PRODUCT LICENSEE(S) or those operating for its
account or third parties who purchase LICENSED PRODUCT(S), LICENSED SERVICE(S)
or DEVELOPED PRODUCT(S) from any of the foregoing entities, develop,
manufacture, market or practice the inventions of LICENSED PRODUCT(S), LICENSED
SERVICE(S) and DEVELOPED PRODUCT(S). Therefore, COMPANY, AFFILIATED COMPANY,
SUBLICENSEE, and DEVELOPED PRODUCT LICENSEE shall indemnify, defend with counsel
reasonably acceptable to LICENSORS, and hold LICENSORS, The Johns Hopkins Health
Systems, their present and former trustees, officers, Inventors of PATENT
RIGHTS, agents, faculty, employees and students harmless as against any
judgments, fees, expenses, or other costs arising from or incidental to any
product liability or other lawsuit, claim, demand or other action brought as a
consequence of the practice of said inventions by any of the foregoing entities,
whether or not LICENSORS or said Inventors, either jointly or severally, are
named as a party defendant in any such lawsuit and whether or not LICENSORS or
the Inventors are alleged to be negligent or otherwise responsible for any
injuries to persons or property. Practice of the inventions covered by LICENSED
PRODUCT(S), LICENSED SERVICE(S) and DEVELOPED PRODUCT(S), by an AFFILIATED
COMPANY or an agent or a SUBLICENSEE(S) or a DEVELOPED PRODUCT LICENSEE(S) or a
third party on behalf of or for the account of COMPANY or by a third party who
purchases LICENSED PRODUCT(S) and LICENSED SERVICE(S), or purchases or licenses
DEVELOPED PRODUCT(S), from COMPANY, shall be considered COMPANY'S practice of
said inventions for purposes of this Paragraph. The obligation of COMPANY to
defend and indemnify as set out in

                                                                            -14-

<PAGE>

                                                                    EXHIBIT 10.4

this Paragraph shall survive the termination of this Agreement, shall continue
even after assignment of rights and responsibilities to an affiliate or
sublicensee, and shall not be limited by any other limitation of liability
elsewhere in this Agreement.

                                    ARTICLE 8
                                 CONFIDENTIALITY

     8.1 CONFIDENTIALITY. If necessary, the COMPANY will exchange information,
which it considers to be confidential. The recipient of such information agrees
to accept the disclosure of said information which is marked as confidential at
the time it is sent to the recipient (the "Confidential Information"), and to
employ all reasonable efforts to maintain the Confidential Information secret
and confidential, such efforts to be no less than the degree of care employed by
the recipient to preserve and safeguard its own confidential information.
Confidential Information that is disclosed orally or visually shall be
documented in a written notice prepared by the Disclosing Party and delivered to
the Receiving Party within thirty (30) days of the date of disclosure; such
notice shall summarize the Confidential Information disclosed to the Receiving
Party and reference the time and place of disclosure The Confidential
Information shall not be disclosed or revealed to anyone except employees of the
recipient who have a need to know the information and who have entered into a
secrecy agreement with the recipient under which such employees are required to
maintain confidential the Confidential Information of the recipient and such
employees shall be advised by the recipient of the confidential nature of the
Confidential Information and that the Confidential Information shall be treated
accordingly.

     All reports produced in accordance with Section 5 of this Agreement shall
be treated as Confidential Information.

     The obligations of this Paragraph shall also apply to AFFILIATED COMPANIES
and/or SUBLICENSEE(S) provided such information by COMPANY. LICENSORS,
COMPANY'S, AFFILIATED COMPANIES, and SUBLICENSEES' obligations under this
Paragraph shall extend until three (3) years after the termination of this
Agreement.

     8.2 EXCEPTIONS. The recipient's obligations under Paragraph 8.1 shall not
extend to any part of the Confidential Information:

          a.   that can be demonstrated to have been in the public domain or
               publicly known and readily available to the trade or the public
               prior to the date of the disclosure; or

          b.   that can be demonstrated, from written records to have been in
               the recipient's possession or readily available to the recipient
               from another source not under obligation of secrecy to the
               disclosing party prior to the disclosure; or

          c.   that becomes part of the public domain or publicly known by
               publication or otherwise, not due to any unauthorized act by the
               recipient; or

                                                                            -15-

<PAGE>

                                                                    EXHIBIT 10.4

          D.   that is demonstrated from written records to have been developed
               by or for the receiving party without reference to Confidential
               Information disclosed by the disclosing party.

          E.   that is required to be disclosed by law, government regulation or
               court order.

                                    ARTICLE 9
                               TERM & TERMINATION

     9.1 TERM. (a) The term of this Agreement shall commence on the EFFECTIVE
DATE and shall continue, in each country on a product by product and country by
country basis, until the date of expiration of the last to expire patent
included within PATENT RIGHTS in that country or if no patents issue then for a
term of twenty (20) years from the EFFECTIVE DATE of this Agreement. (b) The
royalty obligations for the sale or provision of DEVELOPED PRODUCT(S) shall
terminate in any country the later of: (i) with respect to NET SALES, ten (10)
years from the time of first commercial sale of a regulatory approved product;
or, (ii) the expiration of the last to expire of any patents covering the
DEVELOPED PRODUCT(S) issued in that country.

     9.2 TERMINATION BY EITHER PARTY. This Agreement may be terminated by either
Party, in the event that the other Party (a) files or has filed against it a
petition under the Bankruptcy Act, makes an assignment for the benefit of
creditors, has a receiver appointed for it or a substantial part of its assets,
or otherwise takes advantage of any statute or law designed for relief of
debtors or (b) fails to perform or otherwise breaches any of its obligations
hereunder, if, following the giving of notice by the terminating Party of its
intent to terminate and stating the grounds therefor, the Party receiving such
notice shall not have cured the failure or breach within sixty (60) days. In no
event, however, shall such notice or intention to terminate be deemed to waive
any rights to damages or any other remedy, which the Party giving notice of
breach may have as a consequence of such failure or breach.

     9.3 TERMINATION BY COMPANY. COMPANY may terminate this Agreement and the
license granted herein, for any reason, upon giving JHU ninety (90) days written
notice.

     9.4 OBLIGATIONS AND DUTIES UPON TERMINATION. If this Agreement is
terminated, both COMPANY and LICENSORS shall be released from all obligations
and duties imposed or assumed hereunder to the extent so terminated, except as
expressly provided to the contrary in this Agreement. Upon termination, the
Parties shall cease any further use of the other Parties' Confidential
Information disclosed to the receiving Party by the other Party. Termination of
this Agreement, for whatever reason, shall not affect the obligation of either
Party to make any payments for which it is liable prior to or upon such
termination, including, but not limited to, the payments due under Paragraphs
3.1 and 3.2 of this Agreement. Termination shall not affect LICENSORS' right to
recover unpaid royalties, fees, reimbursement for patent expenses, or other
forms of financial compensation incurred prior to termination. Upon termination,
COMPANY shall submit a final royalty report to JHU and any royalty payments,
fees, un-reimbursed patent expenses

                                                                            -16-

<PAGE>

                                                                    EXHIBIT 10.4

and other financial compensation due to LICENSORS shall become immediately
payable. Furthermore, upon termination of this Agreement, all rights in and to
the licensed technology, including PATENT RIGHTS, shall revert immediately to
LICENSORS at no cost to LICENSORS. Upon termination of this Agreement, any
SUBLICENSEE(S) shall become a direct licensee of LICENSORS, provided that
LICENSORS' obligations to SUBLICENSEE(S) are no greater than LICENSORS'
obligations to COMPANY under this Agreement. COMPANY shall provide written
notice of such to each SUBLICENSEE(S) with a copy of such notice provided to
JHU.

     9.5 OBLIGATION REGARDING DEVELOPED PRODUCT(S). Termination shall not affect
COMPANY'S, AFFILIATED COMPANY'S, SUBLICENSEE'S OR DEVELOPED PRODUCT LICENSEES'
obligation under Paragraph 9.1(b) to pay royalty to JHU on a DEVELOPED
PRODUCT(S).

                                   ARTICLE 10
                                  MISCELLANEOUS

     10.1 USE OF NAME. COMPANY, AFFILIATED COMPANIES, SUBLICENSEE(S) and
DEVELOPED PRODUCT LICENSEE(S) shall not use the name of LICENSORS or The Johns
Hopkins Health System or any of their constituent parts, such as the Johns
Hopkins Hospital or any contraction thereof or the name of Inventors in any
advertising, promotional, sales literature or fundraising documents without
prior written consent from an authorized representative of JHU. COMPANY,
AFFILIATED COMPANIES, SUBLICENSEE(S) and DEVELOPED PRODUCT LICENSEE(S) shall
allow at least seven (7) business days notice of any proposed public disclosure
for JHU's review and comment or to provide written consent.

     10.2 NO PARTNERSHIP. Nothing in this Agreement shall be construed to create
any agency, employment, partnership, joint venture or similar relationship among
the Parties other than that of a licensor/licensee. Neither Party shall have any
right or authority whatsoever to incur any liability or obligation (express or
implied) or otherwise act in any manner in the name or on the behalf of the
other, or to make any promise, warranty or representation binding on the other.

     10.3 NOTICE OF CLAIM. Each Party shall give the other or its representative
immediate notice of any suit or action filed, or prompt notice of any claim
made, against them arising out of the performance of this Agreement or arising
out of the practice of the inventions licensed hereunder.

     10.4 PRODUCT LIABILITY. Prior to initial human testing or first commercial
sale of any LICENSED PRODUCT(S), LICENSED SERVICE(S) or DEVELOPED PRODUCT(S) as
the case may be in any particular country, COMPANY shall establish and maintain,
in each country in which COMPANY, an AFFILIATED COMPANY, SUBLICENSEE(S) or
DEVELOPED PRODUCT LICENSEE(S) shall test or sell LICENSED PRODUCT(S), LICENSED
SERVICE(S) or DEVELOPED PRODUCT(S), product liability or other appropriate
insurance coverage in the minimum amount of [**] per claim and will annually
present evidence to JHU that such coverage is being maintained. Upon JHU's
request, COMPANY will furnish JHU with a Certificate of Insurance of each
product liability insurance policy obtained. LICENSORS shall be listed as an

                                                                            -17-

<PAGE>

                                                                    EXHIBIT 10.4

additional insured in said insurance policies. If such Product Liability
insurance is underwritten on a 'claims made' basis, COMPANY agrees that any
change in underwriters during the term of this Agreement will require the
purchase of 'prior acts' coverage to ensure that coverage will be continuous
throughout the term of this Agreement.

     10.5 GOVERNING LAW. This Agreement shall be construed, and legal relations
between the Parties hereto shall be determined, in accordance with the laws of
the State of Maryland applicable to contracts solely executed and wholly to be
performed within the State of Maryland without giving effect to the principles
of conflicts of laws. Any disputes between the Parties to the Agreement shall be
brought in the state or federal courts of Maryland. The Parties agree to waive
their right to a jury trial.

     10.6 NOTICE. All notices or communication required or permitted to be given
by either Party hereunder shall be deemed sufficiently given if mailed by
registered mail or certified mail, return receipt requested, or sent by
overnight courier, such as Federal Express, to the other Party at its respective
address set forth below or to such other address as one Party shall give notice
of to the other from time to time hereunder. Mailed notices shall be deemed to
be received on the third business day following the date of mailing. Notices
sent by overnight courier shall be deemed received the following business day.

     If to COMPANY:     Director, Business Development
                        245 First Street, 15th Floor
                        Cambridge, MA 02142
                        PHONE: (617) 914-3410
                        FAX: (617) 914-3943

     If to JHU:         Johns Hopkins Technology Transfer
                        The Johns Hopkins University
                        100 N. Charles Street
                        5th Floor
                        Baltimore, MD 21201
                        Attn: Director

     If to INSTITUTION: Director
                        Office of Science and Technology
                        Zhejiang University
                        No.38, Zhe Da Road
                        Hangzhou, Zhejiang 310027
                        P.R. China
                        +86 571 87585600
                        +86 571 85128776

     10.7 COMPLIANCE WITH ALL LAWS. In all activities undertaken pursuant to
this Agreement, the Parties covenant and agree that each will in all material
respects comply with such Federal, state

                                                                            -18-

<PAGE>

                                                                    EXHIBIT 10.4

and local laws and statutes, as may be in effect at the time of performance and
all valid rules, regulations and orders thereof regulating such activities.

     10.8 SUCCESSORS AND ASSIGNS. Neither this Agreement nor any of the rights
or obligations created herein, except for the right to receive any remuneration
hereunder, may be assigned by either Party, in whole or in part, without the
prior written consent of the other Parties, except that either Party shall be
free to assign this Agreement in connection with any sale of substantially all
of its assets without the consent of the other. This Agreement shall bind and
inure to the benefit of the successors and permitted assigns of the Parties
hereto.

     10.9 NO WAIVERS; SEVERABILITY. No waiver of any breach of this Agreement
shall constitute a waiver of any other breach of the same or other provision of
this Agreement, and no waiver shall be effective unless made in writing. Any
provision hereof prohibited by or unenforceable under any applicable law of any
jurisdiction shall as to such jurisdiction be deemed ineffective and deleted
herefrom without affecting any other provision of this Agreement. It is the
desire of the Parties hereto that this Agreement be enforced to the maximum
extent permitted by law, and should any provision contained herein be held by
any governmental agency or court of competent jurisdiction to be void, illegal
and unenforceable, the Parties shall negotiate in good faith for a substitute
term or provision which carries out the original intent of the Parties.

     10.10 ENTIRE AGREEMENT; AMENDMENT. The Parties acknowledge that they have
read this entire Agreement and that this Agreement, including the attached
Exhibits constitutes the entire understanding and contract between the Parties
hereto and supersedes any and all prior or contemporaneous oral or written
communications with respect to the subject matter hereof, all of which
communications are merged herein. It is expressly understood and agreed that (i)
there being no expectations to the contrary between the Parties hereto, no usage
of trade, verbal agreement or another regular practice or method dealing within
any industry or between the Parties hereto shall be used to modify, interpret,
supplement or alter in any manner the express terms of this Agreement; and (ii)
this Agreement shall not be modified, amended or in any way altered except by an
instrument in writing signed by all of the Parties hereto.

     10.11 DELAYS OR OMISSIONS. Except as expressly provided herein, no delay or
omission to exercise any right, power or remedy accruing to any Party hereto,
shall impair any such right, power or remedy to such Party nor shall it be
construed to be a waiver of any such breach or default, or an acquiescence
therein, or in any similar breach or default be deemed a waiver of any other
breach or default theretofore or thereafter occurring. Any waiver, permit,
consent or approval of any kind or character on the part of any Party of any
breach or default under this Agreement, or any waiver on the part of any Party
of any provisions or conditions of this Agreement, must be in writing and shall
be effective only to the extent specifically set forth in such writing. All
remedies either under this Agreement or by law or otherwise afforded to any
Party, shall be cumulative and not alternative.

     10.12 FORCE MAJEURE. If either Party fails to fulfill its obligations
hereunder (other than an obligation for the payment of money), when such failure
is due to an act of God, or other circumstances beyond its reasonable control,
including but not limited to fire, flood, civil commotion, riot, war (declared
and undeclared), revolution, or embargoes, then said failure shall be

                                                                            -19-

<PAGE>

                                                                    EXHIBIT 10.4

excused for the duration of such event and for such a time thereafter as is
reasonable to enable the Parties to resume performance under this Agreement,
provided however, that in no event shall such time extend for a period of more
than one hundred eighty (180) days.

     10.13 FURTHER ASSURANCES. Each Party shall, at any time, and from time to
time, prior to or after the EFFECTIVE DATE of this Agreement, at reasonable
request of the other Parties, execute and deliver to the others such instruments
and documents and shall take such actions as may be required to more effectively
carry out the terms of this Agreement.

     10.14 SURVIVAL. All representations, warranties, covenants and agreements
made herein and which by their express terms or by implication are to be
performed after the execution and/or termination or expiration hereof, or are
prospective in nature, shall survive such execution and/or termination or
expiration, as the case may be. This shall include Paragraphs 3.7 (Late
Payments), 5.2 (Records), 9.5 (Obligation regarding DEVELOPED PRODUCTS) and
Articles 6, 7, 8, 9, and 10.

     10.15 NO THIRD PARTY BENEFICIARIES. Nothing in this Agreement shall be
construed as giving any person, firm, corporation or other entity, other than
the Parties hereto and their successors and permitted assigns, any right, remedy
or claim under or in respect of this Agreement or any provision hereof.

     10.16 HEADINGS. Article headings are for convenient reference and not a
part of this Agreement. All Exhibits are incorporated herein by this reference.

     10.17 COUNTERPARTS. This Agreement may be executed in counterparts, each of
which shall be deemed an original and all of which when taken together shall be
deemed but one instrument.

                                                                            -20-

<PAGE>

                                                                    EXHIBIT 10.4

     IN WITNESS WHEREOF, this Agreement shall take effect as of the EFFECTIVE
DATE when it has been executed below, by the duly authorized representatives of
the Parties.

THE JOHNS HOPKINS UNIVERSITY            VIACELL, INC.

/s/ R. Keith Baker                      /s/ Marc D. Beer
-------------------------------------   ----------------------------------------
R. Keith Baker, Ph.D., MBA              Name: Marc D. Beer
Senior Director,                        Title: Chief Executive Officer
Johns Hopkins Technology Transfer
                                        8/29/05
8/29/05                                 (Date)
(Date)

ZHEJIANG UNIVERSITY

-------------------------------------
Name: /s/ Kunsong Chen
      -------------------------------
Title: Director,
       ------------------------------
Office of Science and Technology
-------------------------------------
                      August 24, 2005
                               (Date)

                                                                            -21-

<PAGE>

                                                                    EXHIBIT 10.4

                                    EXHIBIT A

                             LICENSE FEE & ROYALTIES

          [**]

                                                                            -22-

<PAGE>

                                                                    EXHIBIT 10.4

                                    EXHIBIT B

                        QUARTERLY SALES & ROYALTY REPORT

                 FOR LICENSE AGREEMENT BETWEEN _____________ AND
           THE JOHNS HOPKINS UNIVERSITY AND ZHEJIANG UNIVERSITY DATED

                                   ----------

                 FOR PERIOD OF ______________ TO ______________

                TOTAL ROYALTIES DUE FOR THIS PERIOD $___________

<TABLE>
<CAPTION>
PRODUCT                     *JHU     1ST COMMERCIAL      TOTAL NET     ROYALTY   AMOUNT
   ID     PRODUCT NAME   REFERENCE      SALE DATE     SALES/SERVICES     RATE      DUE
-------   ------------   ---------   --------------   --------------   -------   ------
<S>       <C>            <C>         <C>              <C>              <C>       <C>

</TABLE>

*    Please provide the JHU Reference Number or Patent Reference

     This report format is to be used to report quarterly royalty statements to
JHU. It should be placed on COMPANY letterhead and accompany any royalty
payments due for the reporting period. This report shall be submitted even if no
sales are reported.

                                                                            -23-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]